| Printable Copy |
 |
| Printable Copy |
|
PLoS One. 2016 Aug 16;11(8):e0160970. doi: 10.1371/journal.pone.0160970. eCollection 2016.
Haralambieva IH1 Zimmermann MT2 Ovsyannikova IG1 Grill DE2 Oberg AL2 Kennedy RB1 Poland GA1.
There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals.
We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients selected from a cohort of 764 schoolchildren based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response.
We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value≤0.0002 q-value≤0.092) including the top gene CD93 (p<1.0E-13 q<1.0E-09) encoding a receptor required for antigen-driven B-cell differentiation maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93 IL6 CXCL12) chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups.
We identified genes and pathways that explain in part and are associated with neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.